Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation

Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation

Abstract Background Preclinical studies and early clinical trials have shown that targeting cancer neoantigens is a promising approach towards the development of personalized cancer immunotherapies. DNA vaccines can be rapidly and efficiently manufactured and can integrate multiple neoantigens simul...

Full description

Bibliographic Details
Main Authors: Lijin Li, Xiuli Zhang, Xiaoli Wang, Samuel W. Kim, John M. Herndon, Michelle K. Becker-Hapak, Beatriz M. Carreno, Nancy B. Myers, Mark A. Sturmoski, Michael D. McLellan, Christopher A. Miller, Tanner M. Johanns, Benjamin R. Tan, Gavin P. Dunn, Timothy P. Fleming, Ted H. Hansen, S. Peter Goedegebuure, William E. Gillanders
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Genome Medicine
Subjects:
Neoantigen
Polyepitope DNA vaccine
Breast cancer
Online Access:https://doi.org/10.1186/s13073-021-00872-4

Internet

https://doi.org/10.1186/s13073-021-00872-4

Similar Items